All
Phase 3 Trial Launches to Assess EGFR Inhibitor for NSCLC Subset
August 4th 2023Researchers conducting this trial will compare zipalertinib plus chemotherapy with chemotherapy alone in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer with the EGFR exon 20 insertion mutation.